Add time:09/02/2019         Source:sciencedirect.com

18,19-Dihydroxycorticosterone (18,19(OH)2-B) and 18-hydroxy-1 9-norcorticosterone (18-OH-19-nor-B) measurements were carried out on the urine of patients with primary aldosteronism (PA), essential hypertension (EHT), and liver cirrhosis with (LC, SA ( + )) and without (LC, SA( − )) aldosteronism. The separation of these steroids was performed by extraction and high-performance liquid chromatography followed by radioimmunoassay (RIA) with specific antibodies prepared in our laboratory. 18, 19(OH)2-B excretion was elevated in patients with PA (24 ± 5.9 [± SE] μg/24 hr; n = 15) and LC, SA ( + ) (83 ± 9.4 μg/24 hr; n = 8). Values in LC, SA (-) (3.1 ± 1.2 μg/24 hr; n = 8) and in EHT (3.7 ±0.4 μg/24 hr; n = 42) were found to be similar to those in normal subjects (5.5 ± 0.9 μg/24 hr; n = 30). The values of urinary 18-OH-19-nor-B in PA and LC, SA( + ) were higher than in LC, SA(−) EHT and normal subjects (P < 0.05). Values in the latter three groups, as compared with each other, did not show significant alterations. Nothing is known about the biologic relevance of 18,19(OH)2-B and very little about that of 18-OH-19-nor-B, but the latter steroid seems to potentiate experimental renal hypertension. One can speculate about possible roles of both steroids as precursors of other steroids, e.g., the biologically potent mineralocorticoid 19-noraldosterone. The data obtained suggest that it is not relevant to measure the urinary levels of either steroid in these clinical syndromes.

We also recommend Trading Suppliers and Manufacturers of 18-hydroxy-19-norcorticosterone (cas 111594-84-4). Pls Click Website Link as below: cas 111594-84-4 suppliers